

Iris Y Navarro-Millán

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6960414/publications.pdf>

Version: 2024-02-01

34
papers

1,540
citations

566801

15
h-index

476904

29
g-index

35
all docs

35
docs citations

35
times ranked

1786
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 924-939.	1.5	466
2	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1108-1123.	2.9	339
3	Changes in Lipoproteins Associated With Methotrexate Therapy or Combination Therapy in Early Rheumatoid Arthritis: Results From the Treatment of Early Rheumatoid Arthritis Trial. Arthritis and Rheumatism, 2013, 65, 1430-1438.	6.7	124
4	Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatology, 2018, 2, 10.	0.6	99
5	Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. Arthritis and Rheumatology, 2020, 72, 1990-1997.	2.9	96
6	Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Annals of the Rheumatic Diseases, 2016, 75, 341-347.	0.5	63
7	Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. Arthritis and Rheumatology, 2017, 69, 46-57.	2.9	48
8	Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis and Rheumatology, 2016, 68, 577-586.	2.9	43
9	Systematic Review of Tumor Necrosis Factor Inhibitor Discontinuation Studies in Rheumatoid Arthritis. Clinical Therapeutics, 2013, 35, 1850-1861.e1.	1.1	36
10	Racial, ethnic, and healthcare disparities in rheumatoid arthritis. Current Opinion in Rheumatology, 2021, 33, 117-121.	2.0	36
11	Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative Study. Arthritis Care and Research, 2019, 71, 80-87.	1.5	34
12	Validation of the Hip Disability and Osteoarthritis Outcome Score and Knee Injury and Osteoarthritis Outcome Score Pain and Function Subscales for Use in Total Hip Replacement and Total Knee Replacement Clinical Trials. Journal of Arthroplasty, 2020, 35, 1200-1207.e4.	1.5	27
13	Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients. Seminars in Arthritis and Rheumatism, 2013, 43, 137-143.	1.6	18
14	Patients and surgeons provide endorsement of core domains for total joint replacement clinical trials. Arthritis Research and Therapy, 2017, 19, 267.	1.6	16
15	Screening of Hyperlipidemia Among Patients With Rheumatoid Arthritis in the United States. Arthritis Care and Research, 2019, 71, 1593-1599.	1.5	15
16	Association of cardiovascular disease and traditional cardiovascular risk factors with the incidence of dementia among patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2021, 51, 292-298.	1.6	12
17	Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2020, 50, 988-995.	1.6	11
18	Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group. Journal of Rheumatology, 2019, 46, 1179-1182.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?. BMC Rheumatology, 2019, 3, 36.	0.6	7
20	Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis. Rheumatology, 2019, 58, 933-934.	0.9	7
21	Views of primary care physicians and rheumatologists regarding screening and treatment of hyperlipidemia among patients with rheumatoid arthritis. BMC Rheumatology, 2020, 4, 14.	0.6	6
22	Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis. BMC Rheumatology, 2020, 4, 26.	0.6	6
23	The Patients' Perspective of Important Glucocorticoid Effects. Journal of Clinical Rheumatology, 2021, 27, 232-238.	0.5	5
24	Prevalence of Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Dataset. ACR Open Rheumatology, 2022, 4, 300-305.	0.9	5
25	The role of immunomodulatory medications in the treatment of COVID-19. Current Opinion in Rheumatology, 2021, 33, 431-445.	2.0	4
26	AB0252â€¦RACIAL DISPARITIES IN OUTCOMES FOR PATIENTS WITH RHEUMATOID ARTHRITIS UNDERGOING TOTAL KNEE OR TOTAL HIP ARTHROPLASTY. , 2019, , .		3
27	Protocol for the pilot randomized trial of the Cardiovascular Risk assessment for Rheumatoid Arthritis (CARE RA) intervention: a peer coach behavioral intervention. Pilot and Feasibility Studies, 2022, 8, 84.	0.5	3
28	Living in immigrant communities does not impact total knee arthroplasty outcomes: experience from a high-volume center in the United States. BMC Musculoskeletal Disorders, 2019, 20, 67.	0.8	1
29	Reply. Arthritis and Rheumatology, 2021, 73, 549-550.	2.9	1
30	Primary Care Provider Density and Elective Total Joint Replacement Outcomes.. Arthroplasty Today, 2021, 10, 73-78.	0.8	1
31	AB1221â€¦VIEWS OF PRIMARY CARE PHYSICIANS AND RHEUMATOLOGISTS REGARDING SCREENING FOR HYPERLIPIDEMIA AMONG PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
32	AB1348â€¦PERSPECTIVES OF PATIENTS WITH INFLAMMATORY ARTHRITIS REGARDING CARDIOVASCULAR RISK: A QUALITATIVE STUDY. , 2019, , .		0
33	Comment on: Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis: reply. Rheumatology, 2020, 59, 454-455.	0.9	0
34	P092â€¦Patientsâ€™ perceptions of glucocorticoid therapy impact on health-related quality of life during treatment for rheumatic diseases: international development of a treatment-specific patient-reported outcome measure (the Steroid PRO). Rheumatology, 2022, 61, .	0.9	0